114 related articles for article (PubMed ID: 19961648)
21. Protective effect of neoglycoprotein-conjugated muramyl dipeptide against Leishmania donovani infection: the role of cytokines.
Sarkar K; Das PK
J Immunol; 1997 Jun; 158(11):5357-65. PubMed ID: 9164956
[TBL] [Abstract][Full Text] [Related]
22. Prolonged administration of dexamethasone induces limited reactivation of visceral leishmaniasis in chronically infected BALB/c mice.
Rousseau D; Suffia I; Ferrua B; Philip P; Le Fichoux Y; Kubar JL
Eur Cytokine Netw; 1998 Dec; 9(4):655-61. PubMed ID: 9889410
[TBL] [Abstract][Full Text] [Related]
23. Combined liposomal immuno- and chemotherapy of visceral leishmaniasis.
Everlien H; Hockertz S
Arzneimittelforschung; 1999 Nov; 49(11):954-61. PubMed ID: 10604050
[TBL] [Abstract][Full Text] [Related]
24. Cellular and humoral immunity to Leishmania major in genetically susceptible mice after in vivo depletion of L3T4+ T cells.
Sadick MD; Heinzel FP; Shigekane VM; Fisher WL; Locksley RM
J Immunol; 1987 Aug; 139(4):1303-9. PubMed ID: 3112230
[TBL] [Abstract][Full Text] [Related]
25. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
Iborra S; Soto M; Carrión J; Alonso C; Requena JM
Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
[TBL] [Abstract][Full Text] [Related]
26. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis.
Rachamim N; Jaffe CL
J Immunol; 1993 Mar; 150(6):2322-31. PubMed ID: 8450215
[TBL] [Abstract][Full Text] [Related]
27. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
Bhaumik SK; Naskar K; De T
Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
[TBL] [Abstract][Full Text] [Related]
28. Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12/23p40.
Hernández MX; Barçante TA; Vilela L; Tafuri WL; Afonso LC; Vieira LQ
Immunol Lett; 2006 May; 105(1):38-47. PubMed ID: 16466810
[TBL] [Abstract][Full Text] [Related]
29. Infections in immunocompetent and immune-deficient mice with promastigotes of a North American isolate of Leishmania infantum.
Rosypal AC; Zajac AM; Troy GC; Lindsay DS
Vet Parasitol; 2005 Jun; 130(1-2):19-27. PubMed ID: 15893066
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic effect of oral Kalanchoe pinnata leaf extract in murine leishmaniasis.
Da Silva SA; Costa SS; Mendonca SC; Silva EM; Moraes VL; Rossi-Bergmann B
Acta Trop; 1995 Dec; 60(3):201-10. PubMed ID: 8907398
[TBL] [Abstract][Full Text] [Related]
31. Leishmania infantum: prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB/c mice.
Rafati S; Zahedifard F; Azari MK; Taslimi Y; Taheri T
Exp Parasitol; 2008 Mar; 118(3):393-401. PubMed ID: 18093586
[TBL] [Abstract][Full Text] [Related]
32. Leishmania tropica: the identification and purification of metacyclic promastigotes and use in establishing mouse and hamster models of cutaneous and visceral disease.
Lira R; Méndez S; Carrera L; Jaffe C; Neva F; Sacks D
Exp Parasitol; 1998 Jul; 89(3):331-42. PubMed ID: 9676711
[TBL] [Abstract][Full Text] [Related]
33. Isotype patterns of immunoglobulins: hallmarks for clinical status and tissue parasite density in Brazilian dogs naturally infected by Leishmania (Leishmania) chagasi.
Reis AB; Teixeira-Carvalho A; Vale AM; Marques MJ; Giunchetti RC; Mayrink W; Guerra LL; Andrade RA; Corrêa-Oliveira R; Martins-Filho OA
Vet Immunol Immunopathol; 2006 Aug; 112(3-4):102-16. PubMed ID: 16621021
[TBL] [Abstract][Full Text] [Related]
34. Activity of IFN-gamma in experimental Leishmania infantum murine visceral leishmaniasis.
Garin YJ; Sulahian A; Gangneux JP; Derouin F
Pathol Biol (Paris); 1997 Jan; 45(1):48-51. PubMed ID: 9097846
[TBL] [Abstract][Full Text] [Related]
35. Murine cutaneous leishmaniasis: resistance correlates with the capacity to generate interferon-gamma in response to Leishmania antigens in vitro.
Sadick MD; Locksley RM; Tubbs C; Raff HV
J Immunol; 1986 Jan; 136(2):655-61. PubMed ID: 3079789
[TBL] [Abstract][Full Text] [Related]
36. Imprinting of BALB/c mice with low Leishmania infantum parasite dose markedly protects spleen against high-dose challenge.
Ferrua B; Luci C; Le Fichoux Y; Paul A; Marty P
Vaccine; 2006 Jan; 24(5):589-96. PubMed ID: 16157427
[TBL] [Abstract][Full Text] [Related]
37. Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients.
Rafati S; Gholami E; Hassani N; Ghaemimanesh F; Taslimi Y; Taheri T; Soong L
Vaccine; 2007 May; 25(21):4159-69. PubMed ID: 17395340
[TBL] [Abstract][Full Text] [Related]
38. Vaccination with a novel recombinant Leishmania antigen plus MPL provides partial protection against L. donovani challenge in experimental model of visceral leishmaniasis.
Bhardwaj S; Vasishta RK; Arora SK
Exp Parasitol; 2009 Jan; 121(1):29-37. PubMed ID: 18983842
[TBL] [Abstract][Full Text] [Related]
39. Protective effect of Croton caudatus Geisel leaf extract against experimental visceral leishmaniasis induces proinflammatory cytokines in vitro and in vivo.
Dey S; Mukherjee D; Chakraborty S; Mallick S; Dutta A; Ghosh J; Swapana N; Maiti S; Ghorai N; Singh CB; Pal C
Exp Parasitol; 2015; 151-152():84-95. PubMed ID: 25655407
[TBL] [Abstract][Full Text] [Related]
40. Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis.
Mizbani A; Taheri T; Zahedifard F; Taslimi Y; Azizi H; Azadmanesh K; Papadopoulou B; Rafati S
Vaccine; 2009 Dec; 28(1):53-62. PubMed ID: 19818721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
